VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
MRNA
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
MRNAModerna, Inc.
$206.80$82.1B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
MRNA logo

Moderna, Inc.

MRNA
NASDAQ · Vaccines & Infectious Disease
$206.80
At close - Nov 17, 4:00 PM EST - USD
Market Cap$82.06B
P/E-31.9x
52W High$280.80
Volume8.19M
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q3

Quarterly Profit Rebound Fails to Offset Structural Cash Burn

Moderna's Q3 2026 revenue of $1.3B and diluted EPS of $0.38 suggest a commercial rebound, yet trailing-twelve-month revenue remains down 39.2% and the trailing net margin stands at -145.2%, indicating the post-pandemic contraction has not been reversed.

GrowthMixed
ProfitabilityNegative
ValuationReview
TechnicalsMixed
Explore valuation models
MARKET ACTION

MRNA price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

12/12 Beats

EPS beat 12 of last 12 quarters

02

Valuation risk

-190% Peers

P/E is 190% below peer median

03

Market leadership

RS 99 · Leader

High momentum (Outperforming 99% of market)

04

Mixed Trend

Mixed

Price < 50DMA but > 200DMA

Next CatalystEstimated earnings · Feb 6
01

Build the investment case

Start with the evidence for owning the stock and the risks that can break the thesis.

EXECUTIVE THESIS

The Investment Case

Full Analysis
Fundamental Trajectory

Revenue rebounded to $1.3B in Q3 2026 with a 75.8% gross margin, but the 9.9% operating margin follows multiple quarters of losses, including an operating margin of -126.4% in 2025Q4, suggesting the profit may be an isolated event.

Analyst Consensus-32.6% target
Hold(29 analysts)
7 Buy16 Hold6 Sell

The Bull Case

Upside Catalysts

Expanding mRNA product pipeline

Moderna is expected to launch over ten products by 2035, with a focus on respiratory vaccines and immuno-oncology, driving a Revenue CAGR of over +15% from 2026-2035.

Leadership in mRNA technology

Moderna specializes in mRNA therapeutics, leveraging its proprietary technology platform to develop innovative medicines, including vaccines and oncology treatments.

Advancements in oncology pipeline

Moderna is making progress in its personalized cancer vaccine program, including late-stage data and collaborations with Merck, positioning it as a leader in immuno-oncology.

The Bear Case

Key Downside Risks

Market performance

Price History →

Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
MRNA+570.12%
S&P 500 (^GSPC)+7.21%
1-Year Return
MRNA+735.22%
S&P 500 (^GSPC)+10.03%
3-Year Return
MRNA+170.54%
S&P 500 (^GSPC)+55.09%
5-Year Return
MRNA-14.63%
S&P 500 (^GSPC)+46.46%
02

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis
Trailing P/E5Y Low
-30.3x
Forward P/E
N/A
EV/EBITDA
N/A
FCF YieldCash Flow
N/A

Valuation vs 5-Year History

Multiple Range
Metric
Current
5Y Median
Historical Range
Percentile
P/E
-30.3x
9.0x
0th· Low
EV/EBITDA
N/A
7.7x
N/A
Price/FCF
N/A
16.3x
N/A
Current Multiple
5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection
Bear$6.27-97.0%
Base (Fair)$94.92-57.5%
Bull$8.13-96.1%
$6.27 Bear$94.92 Base$8.13 Bull
Current Market Price: $206.80
Trades at a 117.9% premium to Base DCF ($94.92)
Open DCF & Valuation Models →Chart Terminal ↗

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
$1.94B-39.2% YoY
Net income FY25
-$2.82B+20.8% YoY
Free cash flow FY25
-$2.06B+49.1% YoY
Operating margin FY25
-158.1%-34.8 pts YoY
ROIC (FY25)-26.1%
Avg ROIC 5Y43.8%
ROE (TTM)-37.6%
Piotroski Score3 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate12/12 (100%)
Revenue Beat Rate10/12 (83%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Nov 6, 2026
$0.38+134.5%
vs -$1.10
$1.3B+47.5%
vs $890M
Q3 2026
Jul 31, 2026
-$1.97+3.0%
vs -$2.03
$145M+40.9%
vs $103M
Q2 2026
May 1, 2026
-$3.40+23.6%
vs -$4.45
$389M+64.6%
vs $236M
Q1 2026
Feb 13, 2026
-$2.11+16.9%
vs -$2.54
$678M+6.7%
vs $635M
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
Zacks Investment Research·11h ago
Merck Ends Nemtabrutinib Development: What's Next for Its Pipeline?

MRK ends nemtabrutinib development after phase III safety concerns, shifting focus to its expanding pipeline assets.

Seeking Alpha·13h ago
Moderna, Inc. (MRNA) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Moderna, Inc. (MRNA) Presents at Jefferies Global Healthcare Conference 2026 Transcript

MarketBeat·14h ago
Moderna Targets Year-End Cancer Therapy Filing, Sees Multibillion-Dollar Opportunity

Moderna NASDAQ: MRNA is preparing to file a U.S. application for its individualized cancer therapy intismeran by year-end, as executives outlined manufacturing plans and upcoming trial results following positive phase III melanoma data.

Defense World·18h ago
Banco Santander S.A. Sells 30,065 Shares of Moderna, Inc. $MRNA

Banco Santander S.A. lowered its holdings in shares of Moderna, Inc. (NASDAQ: MRNA) by 34.7% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 56,612 shares of the company's stock after selling 30,065 shares during the period. Banco Santander S.A.'s holdings in Moderna were worth $10,902,000

Filtered for Moderna, Inc.More Headlines
04

Compare before deciding

Benchmark MRNA against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Moderna, Inc. (MRNA)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
MRNA logoMRNAModerna, Inc.Current
$206.80$82.06B-31.88-39.23%-110.46%-37.62%—
BNTX logoBNTXBioNTech SE
$84.86$21.32B-13.200.2%-61.28%-8.06%—
NVAX logoNVAXNovavax, Inc.
$7.96$1.31B-17.1164.69%-18.64%——
PFE logoPFEPfizer Inc.
$28.46$162.21B40.58-1.65%6.34%4.58%6.04%
JNJ logoJNJJohnson & Johnson
$278.70$670.89B42.406.05%16.2%19.55%1.83%
AZN logoAZNAstraZeneca PLC
$182.27$284.34B25.888.63%17.68%22.18%1.75%

Compare MRNA vs Peers

Moderna, Inc. (MRNA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs BNTX

Most directly comparable listed peer for MRNA.

Scale Benchmark

vs JNJ

Larger-name benchmark to compare MRNA against a more recognizable public peer.

Peer Set

Compare Top 5

vs BNTX, NVAX, PFE, JNJ

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

MRNA SEC Filings & Documents

Moderna, Inc. (MRNA) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Nov 6, 2026·SEC

Material company update

Jul 31, 2026·SEC

Material company update

Jul 8, 2026·SEC

10-K Annual Reports

2
FY 2026

Feb 20, 2026·SEC

FY 2025

Feb 21, 2025·SEC

10-Q Quarterly Reports

6
FY 2026

Nov 6, 2026·SEC

FY 2026

Jul 31, 2026·SEC

FY 2026

May 1, 2026·SEC

Get notified when MRNA posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

MRNA Frequently Asked Questions

Moderna, Inc. (MRNA) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Moderna, Inc.'s revenue?

Moderna, Inc. (MRNA) reported $2.52B in revenue over the trailing twelve months. Revenue was $1.94B in fiscal year 2025. That is 1693% more than the $108.4M of fiscal year 2016.

How fast is Moderna, Inc. growing?

Moderna, Inc. (MRNA) grew revenue by 13.7% over the trailing twelve months, compared with the twelve months before.

Is MRNA profitable?

No. Moderna, Inc. (MRNA) reported a net loss of $2.79B over the trailing twelve months.

Dividend & Returns
What is MRNA's return on equity?

Moderna, Inc. (MRNA) had a return on equity (ROE) of -37.6% over the trailing twelve months. A negative ROE means the company lost money over the period.

What is Moderna, Inc.'s free cash flow?

Moderna, Inc. (MRNA) had negative free cash flow of $1.95B over the trailing twelve months.

What if you invested $1,000 in MRNA back in 2016?

Total return calculator · dividends reinvested · 10+ years of data

See returns →